Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2004

View Archived Issues

Oral tacrolimus shows promise in steroid-refractory ulcerative colitis

Boehringer Ingelheim scientists claim new antiproliferative agents

New nAChR ligands and their use described by Aventis and Targacept

Novel beta3-adrenoceptor agonists covered by Kissei patent

Non-hemolytic indolicidin-based antibiotics identified by Indian researchers

Optically active calcium antagonists and their use in hypertension and other disorders

New antiangiogenic kinase inhibitors discovered at Cellular Genomics

French team identifies new G-quadruplex-binding telomerase inhibitors

Santaris describes novel potent Bcl-2 inhibitor SPC-2004

ANG-704: A metabolically stable bioreductive prodrug of combretastatin A4

Multiple targets elucidated for anti-GI cancer agent HKH-40A

AP-23573 enters phase II study for bone and soft tissue sarcomas

Pierre Fabre to commercialize Olux in Europe

Enbrel approved in E.U. for psoriasis

Gilead Sciences and Genelabs collaborate in HCV

U.K. approval for QVAR in Easi-Breathe inhaler

GenPat77 and MedImmune sign agreement on novel therapeutic target

Approvable letter for SnET2 for AMD

Tarceva NDA accepted for priority review

Primovist completes European mutual recognition procedure

FDA approves Remicade as first-line therapy in moderate to severe RA

Kissei takes option to Japanese license for YSCMA

RTA-203: a new mammalian V-ATPase inhibitor in preclinical testing

Good pharmacokinetic profiles reported for single-dose and twice-daily LBM-415

A PABA combination regimen shows promise in refractory melanoma

New data on the bactericidal activity of RO-4908463

Abilify approved for acute bipolar mania

Doripenem shows good antibacterial activity against a large number of clinical isolates

Single oral doses of palosuran are reported safe in healthy volunteers

DA-9601 increases ghrelin, leptin in peptic ulcer models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.